British scientists have found thousands of genes linked to the survival of cancer, including haematological cancers, in the largest research project of its kind.
The Wellcome Sanger Institute and another research organisation, Open Targets, published their findings in Nature.
The scientists used CAS9 knock-out screens to disrupt genes in 30 types of human cancer cell lines, targeting 20,000 protein coding genes.
Researchers report they have identified more than 600 genetic targets across these cancer cell-lines as potential therapeutic targets.
They have called their findings the Cancer Dependency Map (DEPMAP), as it outlines the cancer's vulnerabilities.
The cancers in the study included the most common – lung, colon and breast – together with those that are currently the hardest to treat, such as those of the ovaries, lung and pancreas.
The list included plasma cell myeloma, acute myeloid leukaemia and B cell non-Hodgkin`s lymphoma.
They further demonstrate the robustness of their knock out screen by identifying Werner syndrome RecQ helicase (WRN) as a target in cancers with faulty DNA repair pathways, loss of WRN results in a lethal cell phenotype.
Researcher Dr Mathew Garnett, from the Wellcome Sanger Institute and Open Targets, said: “The Cancer Dependency Map is a huge effort to identify all the weaknesses that exist in different cancers so we can use this information to empower the next generation of precision cancer treatments.
"Ultimately we hope this impacts on the way we treat patients, so many more patients get effective therapies. In the meantime, this tool will be freely available for scientists across the world to understand what makes a cancer a cancer, and how we might target different types of cancers much more effectively than we do today.”
Fellow researcher Dr Fiona Behan said: “With the Cancer Dependency Map, I really hope to revolutionise treatment for patients. I didn’t get in this game to generate long lists of priority targets, I want to make a difference in a patient’s life.
"Even a handful of new, more effective anti-cancer drugs in the clinic or an improvement in the drug development process as a result of this research would benefit an enormous number of patients.”
The Charity Cancer Research UK said the work was a "salient leap."
Chief scientist Professor Karen Vousden added: "We should remember that studying cells in the lab doesn’t always reflect the complexities of cancer in the human body and so will not necessarily reflect how someone will respond to a drug.
"This work provides some excellent starting points and the next steps will be a thorough analysis of the genes that have been identified as weaknesses in this study, to determine if they will one day lead to the development of new treatments for patients.”
You can investigate the DEPMAP yourself at the Sanger Institute’s dedicated website here: https://depmap.sanger.ac.uk
Source: Fiona Behan et al. Prioritisation of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 10 April 2019; doi: 10.1038/s41586-019-1103-9
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/